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Abstract
Background: Preventing ventilator-associated lung injury (VALI) has become pivotal in mechanical ventilation of
patients with acute lung injury (ALI) or its more severe form, acute respiratory distress syndrome (ARDS). In the
present study we investigated whether plasma levels of lung-specific biological markers can be used to evaluate
lung injury in patients with ALI/ARDS and patients without lung injury at onset of mechanical ventilation.
Methods: Plasma levels of surfactant protein D (SP-D), Clara Cell protein (CC16), KL-6 and soluble receptor for
advanced glycation end-products (sRAGE) were measured in plasma samples obtained from 36 patients - 16
patients who were intubated and mechanically ventilated because of ALI/ARDS and 20 patients without lung injury
at the onset of mechanical ventilation and during conduct of the study. Patients were ventilated with either a
lung-protective strategy using lower tidal volumes or a potentially injurious strategy using conventional tidal
volumes. Levels of biological markers were measured retrospectively at baseline and after 2 days of mechanical
ventilation.
Results: Plasma levels of CC16 and KL-6 were higher in ALI/ARDS patients at baseline as compared to patients
without lung injury. SP-D and sRAGE levels were not significantly different between these patients. In ALI/ARDS
patients, SP-D and KL-6 levels increased over time, which was attenuated by lung-protective mechanical ventilation
using lower tidal volumes (P = 0.02 for both biological markers). In these patients, with either ventilation strategy
no changes over time were observed for plasma levels of CC16 and sRAGE. In patients without lung injury, no
changes of plasma levels of any of the measured biological markers were observed.
Conclusion: Plasma levels of SP-D and KL-6 rise with potentially injurious ventilator settings, and thus may serve as
biological markers of VALI in patients with ALI/ARDS.
Background
Acute lung injury (ALI) and its more severe form, acute
respiratory distress syndrome (ARDS) are life-threaten-
ing conditions with mortality rates up to 40% [1,2]. Pre-
vention of additional lung injury caused by mechanical
ventilation is a key element of care in these patients [3].
Clinical trials have demonstrated that non-protective
forms of mechanical ventilation can cause additional
pulmonary damage in patients with ALI/ARDS,
frequently referred to as ventilator-associated lung injury
(VALI) [2,4-6].
Development of VALI is not easily recognizable and
therefore also not always preventable. One strategy fre-
quently used to assess development of VALI is measure-
ment of bronchoalveolar lavage fluid levels of proteins
involved in the pathophysiology of lung injury. Several
proteins have been suggested as possible biological mar-
kers of ALI/ARDS [7,8], and could potentially be used
to monitor increased pulmonary inflammation asso-
ciated with VALI [9]. However, obtaining bronchoalveo-
lar lavage fluid may not always be possible and requires
bronchoscopy expertise. In addition, respiratory and
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scopy and subsequent lavage may hamper routine use of
local levels of biological markers.
Systemic markers are far more easy to obtain, and can
also be obtained more frequently. Several studies have
shown systemic levels of proteins which occur naturally
only in high levels in the pulmonary compartment to
increase in patients with ALI/ARDS [10-13]. These
include surfactant protein (SP)-D, Clara cell protein
(CC16), KL-6 and soluble receptor for advanced glyca-
tion end-products (sRAGE). Although the process of
entrance of proteins from the pulmonary compartment
to the circulation has not yet been unraveled in detail,
the increases in the systemic compartment have been
ascribed to leakage across the alveolocapillary mem-
brane, in association with the development of VALI
[14]. ARDS is characterized by endothelial injury and
increased vascular permeability [15] and it has been pos-
tulated that the alveolocapillary membrane has been
damaged to such extent that pulmonary proteins diffuse
under a concentration gradient to the circulation in
patients with ALI/ARDS [16]. Increases in systemic
levels of these proteins may thus be indicative of lung
injury. Because of this pathophysiological relation, in
theory these proteins may be better markers of ALI/
ARDS as compared to proteins involved in inflammation
as cytokines or clotting proteins, as they may be more
specific for lung injury.
In the present study we investigated whether plasma
levels of SP-D, CC16, KL-6 and sRAGE can be used in
the evaluation of lung injury. We first analyzed whether
plasma levels are associated with the lung injury score
(LIS) [17] in patients with and without ALI/ARDS. We
hypothesized plasma protein levels to be increased more
in patients with the higher LIS. Furthermore, because
worsening lung injury may be associated with bigger
gaps in the alveolocapillary membrane, we hypothesized
that the larger proteins SP-D and KL-6 would be more
informative about the pulmonary status than levels of
the smaller proteins CC16 and sRAGE. Second, we ana-
lyzed whether plasma levels of these biological markers
change in patients ventilated with lung-protective or
potentially injurious ventilation strategies. Third, the
association between plasma levels and mortality, number
of days on the ventilator and length of stay in hospital
were studied.
Methods
Patients
Saved samples of patients with ALI/ARDS who partici-
pated in a previously reported multicenter study com-
paring lung-protective with conventional mechanical
ventilation were collected [4]. Patients fulfilled the con-
sensus criteria for ALI/ARDS and had an anticipated
duration of mechanical ventilation of at least 48 hours.
Next, samples of the first 20 consecutive patients with-
out lung injury at onset of mechanical ventilation from
a study comparing lung-protective with conventional
mechanical ventilation were collected [18]. These
patients also had an expected duration of mechanical
ventilation of at least 48 hours. The study protocols of
both studies were approved by the institutional review
board of the participating hospitals. Informed consent
was obtained from every patient or the closest relative.
Mechanical ventilation protocols
ALI/ARDS patients were randomized to one of two
mechanical ventilation protocols as described previously
[4]. In short, in the conventional protocol the respira-
tory rate was set at 10 - 15 breaths per minute and the
tidal volume was set to maintain an arterial carbon
dioxide pressure of 35 - 40 mm Hg. However, for safety
reasons, the plateau pressure could not exceed 35 cm
H2O irrespective of arterial carbon dioxide pressure. In
the lung-protective protocol, the plateau pressure was
set at the upper inflection point of the pressure volume
curve of the lung while the level of positive end expira-
tory pressure (PEEP) was set 1 - 3 cm H2O above the
lower inflection point.
Patients without lung injury at onset of mechanical
ventilation were randomized to a conventional protocol
using tidal volumes of 10 ml/kg ideal body weight
(IBW), or a lung-protective protocol using tidal volumes
of 6 ml/kg IBW. Respiratory rate and levels of PEEP
were set at the discretion of the attending physician.
Sample collection
Blood samples were drawn from a central venous line
into vacutainers containing heparin on the day of inclu-
sion and after 48 hours. Immediately thereafter, samples
were centrifuged at 1500 × g for 10 minutes. The super-
natant was collected and samples were stored at - 80°C
until analysis.
Measurements
Levels of SP-D, CC16 and sRAGE were measured with
an enzyme-linked immunoassay (ELISA) as described
before [19]. Different from previous measurements
another capture antibody was used (clone HM3022,
HyCult, Uden, The Netherlands). An enzyme immuno
assay for measurement of KL-6 was kindly offered by
Sanko Junyaku Co Ltd (Tokyo, Japan).
Lung injury score
To assess lung injury in patients the lung injury score
(LIS) was determined [17]. This was done by two mem-
bers of the study group who were blinded for the mea-
surements of pulmonary proteins.
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Page 2 of 9Statistical analysis
Descriptive results of continuous data were expressed as
means with standard deviations for parametric data or
as medians with ranges for non-parametric data. To
identify differences between groups analysis of variance,
the Kruskal-Wallis, c
2-o rF i s h e r ’s exact statistics were
used as appropriate. Baseline correlations between pro-
tein levels and LIS were assessed with Spearman’sr h o .
To study the relation between pulmonary protein levels
and the LIS over time, a linear mixed model was con-
structed. In this model serial measurements were com-
bined to investigate the association between LIS and
protein levels. In this way, we were able to investigate
t h ee f f e c to fa ni n c r e a s ei np r o t e i nl e v e lo nt h eL I Sa n d
thereby investigating our hypothesis that larger proteins
w o u l db em o r ei n f o r m a t i v eo nc h a n g e si nL I S .W e
repeated this analysis while controlling for presence of
pulmonary disease or non-pulmonary disease and age.
To investigate whether mechanical ventilation protocol
would influence protein levels, a second linear mixed
model was constructed in which changes in protein
levels over time were studied while controlling for
mechanical ventilation protocol (conventional or protec-
tive). Finally, the association between protein levels and
mortality, length of stay in hospital and number of days
on the ventilator were studied. A two-sided P-value <
0.05 was considered as statistically significant. All ana-
lyses were done with SPSS, version 14.
Results
Patients
Sixteen patients with ALI/ARDS and 20 patients without
lung injury at the onset of mechanical ventilation were
studied. The demographic data and baseline data are
presented in table 1. There were no differences in base-
line characteristics, neither between the ALI/ARDS
groups nor in between the patients groups without lung
injury at onset. Patients in the second study did not
develop ALI/ARDS during conduct of the study. As
expected, LIS was higher in patients with ALI/ARDS as
compared to patients without lung injury.
Respiratory parameters
Tidal volumes differed significantly between the two
ventilation strategies, both in ALI/ARDS patients and
patients without lung injury at onset of mechanical ven-
tilation (figure 1). While maximum airway pressures
were significantly higher in both ALI/ARDS groups,
tidal volumes and respiratory rates applied in patients
without lung injury at onset of mechanical ventilation
were comparable with those in patients in the lung-pro-
tective ALI/ARDS group.
Association between proteins levels and LIS
The baseline protein levels are displayed in table 2. ALI/
ARDS patients had higher plasma levels of SP-D, CC16
and KL-6, as compared to patients without lung injury
at onset of mechanical ventilation, although statistical
significance was not reached for SP-D. Plasma levels of
sRAGE were comparable between patients from the two
studies. Baseline correlations between LIS and protein
levels were significant for SP-D, CC16 and KL-6, (r =
0.35, 0.40, and r = 0.31, respectively, P <0 . 0 1f o ra l l ,
figure 2).
Linear mixed model analysis showed that both CC16
and KL-6 were associated with the LIS over time but
the strongest association was found with CC16. A
change of 10 ng/ml of CC16 was associated with a
change of 0.4 (95%-CI 0.2 - 0.6) of LIS (P =0 . 0 0 1 ) .A
change of 100 U/l of KL-6 was associated with a change
of 0.2 (95%-CI 0.08 - 0.28) of LIS (P = 0.001). On multi-
variate analysis, controlling for age and presence of
Table 1 Baseline characteristics
ALI/ARDS
Lung-protective
(n = 8)
ALI/ARDS
Conventional
(n = 8)
P-value no lung injury
Lung-protective
(n = 10)
no lung injury
Conventional
(n = 10)
P-value
Age (yrs) 58 ± 18 58 ± 22 0.97 57 ± 19 58 ± 19 0.82
Male sex, No. (%) 4 (50%) 4 (50%) 0.80 7 (70%) 7 (70%) 1.00
APACHE II score 14.8 ± 2.4 14.1 ± 2.0 0.58 13.8 ± 2.3 15.2 ± 1.5 0.78
LIS 2.2 ± 0.4 2.3 ± 0.5 0.74 0.7 ± 0.7 0.7 ± 0.7 0.92
Admission diagnosis 0.43 0.41
Resuscitation 74
Neurological disease 22
Cardiopulmonary surgery 2
Sepsis 4 3 1
Trauma 1 3 1 1
Pneumonia 3 2
ALI acute lung injury; ARDS acute respiratory distress syndrome; APACHE acute physiology and chronic health evaluation; LIS lung injury score. Values are
displayed as means with standard deviation.
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Page 3 of 9pneumonia, KL-6 was an independent predictor of the
LIS (P = 0.004) together with presence of pneumonia (P =
0.03). An increase of 100 U/l of KL-6 was associated with
an increase of 0.18 (95%-CI 0.07 - 0.30) of LIS while pre-
sence of pneumonia was associated with an increase of
0.97 (95%-CI 0.8 - 1.15).
Plasma levels of pulmonary proteins with different
ventilator settings
In the next step we investigated the relation between
mechanical ventilation protocol and plasma protein
levels. As mechanical ventilation protocols were
different amongst patients with and without ALI/ARDS,
this analysis was performed for each group separately.
In univariate analysis, plasma levels of SP-D increased
significantly after 48 hours in ALI/ARDS patients (275
[80-462] ng/ml to 487 [278-776] ng/ml, P < 0.001). This
increase was significantly smaller in ALI/ARDS patients
ventilated with the lung-protective strategy (P =0 . 0 2
versus conventional). Levels of CC16 remained
unchanged over time in both ALI/ARDS groups and no
significant differences were seen between these groups
(P = 0.27 versus conventional). Levels of KL-6 increased
in ALI/ARDS patients who received conventional
mechanical ventilation but remained stable in the lung-
protective ALI/ARDS group (figure 3, P =0 . 0 2v e r s u s
conventional). In contrast, sRAGE levels declined in the
conventional group while they remained constant in the
lung-protective group (P = 0.03 versus lung-protective).
In patients without lung injury at onset of mechanical
ventilation no changes were seen over time in any of
the studied markers.
We performed a multivariate analysis controlling for
presence of pneumonia only for SP-D and KL-6. In mul-
tivariate analysis, both SP-D and KL-6 levels were
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Figure 1 Mechanical ventilation parameters. Mechanical ventilation parameters in patients with ALI/ARDS (circles) and without lung injury at
onset of mechanical ventilation (squares). Open symbols: patients ventilated with a lung-protective mechanical ventilation strategy with lower
tidal volumes; closed symbols: patients ventilated with a potentially lung-injurious strategy using conventional tidal volumes. VT, tidal volume;
Pmax, maximum airway pressure.
Table 2 Baseline plasma protein levels
ALI/ARDS
(n = 16)
No lung injury
(n = 20)
P-value
SP-D (ng/ml) 275 [80 - 462] 140 [84 - 216] 0.09
CC16 (ng/ml) 14.3 [9.0 - 19.0] 7.7 [4.8 - 13.5] 0.03
KL-6 (U/l) 477 [287 - 636] 240 [160 - 304] 0.001
sRAGE (pg/ml) 1000 [300 - 1500] 725 [532 - 1660] 0.59
ALI acute lung injury; ARDS acute respiratory distress syndrome; SP-D
surfactant protein D, CC16 Clara cell protein, sRAGE soluble receptor for
advanced glycation end products. Values are displayed as medians with
interquartile range.
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Page 4 of 9significantly influenced by mechanical ventilation proto-
col (P = 0.04) while presence of pneumonia was not sig-
nificantly associated.
Association between plasma protein levels and clinical
outcome
We examined whether plasma levels of biomarkers were
related to mortality, length of stay (LOS) and the num-
b e ro fd a y so nt h ev e n t i l a t o ri nt h eA L I / A R D Sg r o u p .
Five ALI/ARDS patients of the conventional group and
3 ALI/ARDS patients of the lung-protective group died.
Non-survivors were more likely to show increases in SP-
D and KL-6 levels as compared to survivors (P = 0.01).
No association was found between CC16 or sRAGE
levels and mortality. Both the baseline level of SP-D and
KL-6 were significantly associated with the number of
days on the ventilator (P = 0.04 for both) and length of
stay in hospital (P = 0.04 and P = 0.03, respectively)
Discussion
We investigated whether plasma levels of SP-D, CC16,
KL-6 and sRAGE could be used for evaluation of lung
injury in critically ill mechanically ventilated patients.
Plasma levels of both CC16 and KL-6 were associated
with the LIS but the strongest association was found
with CC16. However, while CC16 levels remained
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Figure 2 Baseline biomarker levels and lung injury score. Scatter plots of baseline levels of surfactant protein D (SP-D), Clara cell protein
(CC16), KL-6 and soluble receptor for advanced glycation end products (sRAGE) as a function of lung injury score (LIS). The correlation is
expressed as Spearman’s rho (r).
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Page 5 of 9unchanged over time, SP-D and KL-6 levels increased in
ALI/ARDS patients when ventilated with a conventional
mechanical ventilation protocol. Moreover, plasma levels
of SP-D and KL-6 were significantly associated with
mortality, the number of days on the ventilator and
length of stay in hospital in patients with ALI/ARDS.
Several limitations of our study have to be acknowl-
edged. First, we included a limited number of patients.
The primary goal of the study was to investigate
whether biological markers were associated with the LIS
in mechanically ventilated patients. As a second goal we
investigated whether mechanical ventilation strategy
would influence levels of these biological markers. Our
sample size was limited because it is unethical to subject
ALI/ARDS patients to a potentially injurious strategy for
a prolonged period of time. As such, we used samples
collected in the course of a previous clinical trial [4],
before it was certain that lung-protective mechanical
ventilation protects against VALI. A second shortcoming
is that we included patients with different etiologies for
ALI/ARDS. Since the pathophysiology of ALI/ARDS
caused by indirect causes (e.g., sepsis) may be different
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Figure 3 Biomarker levels per group at two time points. Levels of surfactant protein D (SP-D), Clara cell protein (CC16), KL-6 and soluble
receptor for advanced glycation end products (sRAGE) in patients without lung injury at onset of mechanical ventilation (no lung injury) and
ALI/ARDS patients (ALI/ARDS), ventilated with either lung-protective mechanical ventilation (open boxes) or potentially lung-injurious mechanical
ventilation (grey boxes). In each group, the left bar represents T = 0 hours, the right bar represents T = 48 hours after inclusion. Box plots
represent 25
th,5 0
th and 75
th percentile; whiskers represent values within 10
th and 90
th percentile; “°” represent outliers and “*” represent extreme
outliers. # P < 0.05 for difference in absolute values between groups at baseline; ‡ P < 0.05 for difference in increases over time between groups.
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Page 6 of 9from direct causes (e.g., pneumonia), it may be that
plasma levels of pulmonary proteins are also different
patients or pneumonia patients with ALI/ARDS. While
we performed multivariate analysis controlling for this
issue, this may still have influenced our results due to
the small sample size. Also, a number of patients with-
out lung injury at onset of mechanical ventilation had
cardiopulmonary resuscitation after cardiac arrest or
had severe trauma which may have caused slight contu-
sion of the lungs which may have influenced baseline
plasma levels of pulmonary proteins. Finally, we studied
patients ventilated with a ventilation protocol which is
no current practice anymore. However, in order to
study the possibility that biomarkers may detect VALI, a
setting is needed in which patients have obvious VALI.
From there, additional studies need to investigate
whether these biomarkers can detect beginning lung
injury in patients ventilated with current ventilation
strategies. It has been shown that protective mechanical
ventilation strategies may still be injurious in some
patients with severe lung injury [9]. Although CC16 cor-
related better with the LIS than SP-D or KL-6, our
results showed that the latter two biomarkers increase
in patients with VALI. Therefore, future studies should
investigate whether these biomarkers are able to detect
lung injury in patients ventilated with current ventilation
strategies.
Our results show that biological markers may be use-
ful in monitoring lung injury in critically ill mechanically
ventilated patients. While in univariate analysis, SP-D,
CC16 and KL-6 were all associated with the LIS, in mul-
tivariate analysis only KL-6 was independently asso-
ciated with the LIS. Furthermore, our data suggest that
plasma KL-6 levels might be used to monitor lung
injury in patients receiving mechanical ventilation. How-
ever, before biomarkers can be implemented as a surro-
gate method to diagnose lung injury, a large clinical
study is needed to answer the question whether biomar-
kers or a combination of biomarkers with clinical para-
meters are better than the LIS or NAECC criteria. In
this light, it is also of interest to test biomarker levels
against methods that measure extravascular lung water
or radionuclide methods of assessing capillary protein
permeability [20]. Although these methods are more
time-consuming than biomarker measurement, no study
has ever compared these methods with these biomarkers
in detecting lung injury.
We did not observe any differences in the non-ALI
group between conventional and lower tidal volume
strategies. The small number of patients and the hetero-
geneity of this patients group may have accounted for
this negative finding. Previous studies suggest that lung
injury develops in non-ALI patients if submitted to con-
ventional tidal volumes during surgery [21,22]. These
studies were however much more controlled, i.e. sam-
pling time and more comparable patient groups, which
may have lead to lower variability in the measured
variables.
Our data are, at least in part, in line with results from
a previous study. In a sub-analysis of the ARDS Net-
work trial comparing lower tidal volumes with conven-
tional tidal volumes systemic levels of SP-D increased
during the first 3 days of mechanical ventilation [10].
We found both SP-D and KL-6 to increase in patients
who were ventilated with a conventional ventilation
strategy. Two pathophysiological processes may account
for this finding. First, in patients with ALI/ARDS the
lung blood barrier is damaged which may result in
increased passive leakageo fS P - Da n dK L - 6f r o mt h e
lungs to the circulation. Secondly, ALI/ARDS is also
characterized by strong proliferation of alveolar type II
cells. Indeed, experimental rat models showed systemic
SP-D levels to increase after instillation of keratinocyte
growth factor in the lungs which causes strong prolifera-
tion of alveolar type II cells without signs of lung injury
[23]. Moreover, the production of SP-D and KL-6 by
alveolar type II cells in humans is increased during
states of proliferation [24]. Therefore, both damage to
the alveolocapillary membrane and proliferation of
alveolar type II cells may result in increased plasma
levels of SP-D and KL-6.
Surprisingly, we did not show any increases in CC16
or sRAGE levels in ALI/ARDS patients ventilated with
conventional mechanical ventilation. Both SP-D and KL-
6 are produced by alveolar type II cells during the pro-
liferative phase while RAGE and CC16 are not. Elevated
levels of CC16 or sRAGE during ALI/ARDS have been
ascribed to damaged epithelium (type I cells) with an
ensuing increased alveolar epithelial permeability [11].
Although proliferation is likely to occur later in the
sequence of ALI/ARDS, the absence of increased CC16
or sRAGE levels in the conventional group may indicate
proliferation of alveolar type II cells as the primary
source of increased SP-D and KL-6 levels.
As explained above, a problem with using serum SP-D
and KL-6 as biological markers is that we don’tf u l l y
understand the biology leading to the increased systemic
levels of these proteins in patients with ALI/ARDS.
From studies in patients with interstitial lung disease,
which is characterized by severe proliferation and fibro-
sis, it is known that increases in plasma levels of SP-D
and KL-6 imply enhanced proliferation and worsening
of the disease [25]. Therefore, increases in plasma levels
of SP-D and KL-6 in patients with ALI/ARDS may indi-
cate progression to the proliferative phase. As with
patients with interstitial fibrosis, patients with the most
abundant proliferation may have the worst outcomes.
We observed the largest increases in SP-D and KL-6
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these markers were measured in the periods of 1-3 days
after diagnosis was made. It was therefore unknown
whether extensive proliferation was already present. If
these markers are to be implemented in clinical practice,
more knowledge on these pathophysiological issues in
ALI/ARDS patients is needed.
Conclusions
Systemic levels of lung proteins may be useful for eva-
luation of lung injury in critically ill mechanically venti-
lated patients. Both systemic SP-D and KL-6 levels
increase in ALI/ARDS patients who are ventilated with
potentially injurious forms of mechanical ventilation.
Moreover, systemic levels of SP-D and KL-6 are asso-
ciated with mortality, duration of mechanical ventilation
and length of stay in hospital. Before these markers can
by implemented in routine clinical practice, not only
additional information on alveolar type II cells and SP-D
and KL-6 production in ALI/ARDS patients is needed
but also a study comparing the use of biomarkers with
current clinical ALI/ARDS scores as the LIS and
NAECC criteria.
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